Key Assessment and Evaluation Strategies After CAR T-Cell Therapy

CAR T-cell therapy is becoming more widely available and more frequently used given the availability of commercial CAR T-cell products and the approvals of multiple agents in the last 2-3 years.  This presents a unique set of issues surrounding the assessment and management of patients outside of clinical trials in community settings.  The management of adverse effects, including toxicity from treatment as well as the education of patients and the coverage of these treatments by insurance are imperative to good clinical care of patients receiving these therapies.

Target Audience

This program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Define CAR T-cell therapies and their uses in clinical practice. 
  • Describe the mechanism of action in the treatment of disease and how this relates to adverse effects. 
  • Understand the assessment and strategies for the prevention and management of CAR T-cell adverse events.

You may also be interested in

Supportive Oncology Care

Many health care professionals have had limited education on supportive care topics and have learned on the job. The guidelines and literature continue to advance supportive oncology care.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Kite, A Gilead Company
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

This activity is supported by an independent medical education grant from Pfizer Inc. 

This activity is supported by an independent educational grant from Incyte Corporation.

Course summary
Available credit: 
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
12/15/2022
Course expires: 
12/15/2023
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2022 Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™

Nancy Cruz Sitner, ANP-BC, BMTCN
Memorial Sloan Kettering Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Nancy Cruz Sitner, ANP-BC, BMTCN

NCCN Staff Disclosures 

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.

Available Credit

  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing